-
Founded in:
2006-06-19 -
Country:
China -
Address:
No. 60, Shunkang Road, Linhe Industrial Development Zone, Shunyi District, Beijing -
Tax NO.:
91110113740421011B -
Registered Funds:
70.50281 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| DIOXOPROMETHAZINE HCL |
It has a strong antitussive effect, and has antihistamine, smooth muscle spasm relief, anti-inflammatory and local anesthetic effects. The antitussive effect usually appears 30-60 minutes after taking the medicine, and the effect lasts for 4-6 hours or longer.
More
It has a strong antitussive effect, and has antihistamine, smooth muscle spasm relief, anti-inflammatory and local anesthetic effects. The antitussive effect usually appears 30-60 minutes after taking the medicine, and the effect lasts for 4-6 hours or longer. |
13754-56-8 | 6 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Roxithromycin |
This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. Its effect on Gram-positive bacteria is slightly worse than that of erythromycin, and its effect on Legionella pneumophila is stronger than that of erythromycin. Its antimicrobial effect on Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P position), blocking the transfer RNA (t-RNA) from binding to the P position, and also blocking the transfer of the polypeptide chain from the acceptor position (A position) to the P position, thereby inhibiting bacterial protein synthesis.
More
This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. Its effect on Gram-positive bacteria is slightly worse than that of erythromycin, and its effect on Legionella pneumophila is stronger than that of erythromycin. Its antimicrobial effect on Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P position), blocking the transfer RNA (t-RNA) from binding to the P position, and also blocking the transfer of the polypeptide chain from the acceptor position (A position) to the P position, thereby inhibiting bacterial protein synthesis. |
80214-83-1 | 28 |